Lupin receives EIR from USFDA for Nagpur injectable facility
The EIR was issued following an inspection of the facility from September 8 to September 16, 2025
The EIR was issued following an inspection of the facility from September 8 to September 16, 2025
Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease
Ryght AI tackles these hurdles with its AI Site Twin platform
Indoco received the Establishment Inspection Report from the USFDA for its API manufacturing facility
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA
The Healey ALS Platform Trial is a multicenter, double-blind, placebo-controlled
The product will be marketed by Dr. Reddy's Laboratories Inc.
Subscribe To Our Newsletter & Stay Updated